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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: The bacterium Chlamydia pneumoniae is associated with respiratory
diseases and nonrespiratory illnesses like atherosclerosis. This study aims to investigate the
seroprevalence of immunoglobulin G (IgG) against C. pneumoniae in an asymptomatic popula-
tion in Jordan and to analyze the immunity state in relation to age and sex.
Methods: Serum samples were collected from 588 apparently healthy individuals aged 2e86
years. Using the microimmunofluorescence (MIF) test, seropositivity was defined as an anti-
C. pneumoniae IgG titer 1:16. Titers from 1:16 to 1:256 were considered indicative for a past
infection, whereas 1:512 was considered diagnostic of an acute infection.
Results: The overall prevalence of C. pneumoniae was 54.9%. The mean seropositivity in males
was slightly higher than females. The seroprevalence of infection was relatively low in children
aged 2e9 years, and steadily increased to reach a plateau of 66.7% at around 30e39 years of
age, which remained stable in later years. Recent infection was indicated in 14.3% of study
subjects. The seropositivity was highest in males, and more frequent in adults than in children
and teenagers.
Conclusion: A high seroprevalence of C. pneumoniae in the asymptomatic population suggests
that infection with this pathogen is common in Jordan. Higher seropositivity in males compared
to females was observed. The primary infection is acquired during the first four decades of life,
and in older ages high antibody levels are likely maintained by reinfection or persistent infec-
tion.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.o.
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.04.004
Seroepidemiology of Chlamydia pneumoniae in Jordan 413Introduction
Chlamydia pneumoniae, recognized as a new species in
1989,1 causes lower and upper respiratory tract infections
in humans and causes about 10% of the community-acquired
pneumonia cases worldwide.1,2 Persistent C. pneumoniae
infections have been implicated in several chronic diseases,
such as asthma, chronic obstructive pulmonary disease, and
cough.3e5 This pathogen has attracted increasing attention
due to its association with chronic atherosclerosis and
coronary heart disease,3,6,7 as shown by seroepidemiology
and presence of the bacterium in atherosclerotic plaques.
C. pneumoniae is transmitted from person to person by
nasal droplets. Seroepidemiological analyses have shown
that respiratory tract infections caused by C. pneumoniae
occur throughout the world.7 Outbreaks of infection have
been reported in families, at schools, military bases, and
work places.1,8e10 It is estimated that all people are
infected by the age of 20 years and acquire at least one
C. pneumoniae infection during their lifetime.11,12 It has
also been suggested that asymptomatic infections or res-
piratory infections with mild symptoms are common.1
About 40e86% of asymptomatic adults in different parts
of the world have antibodies to C. pneumoniae.8,13e25
Cultivation of C. pneumoniae in a cell culture system is
technically complex and, therefore, it is not routinely used
for detection of the pathogen in clinical specimens. How-
ever, more rapid diagnostic techniques such as the poly-
merase chain reaction (PCR), antigen immunoassay, and
direct immunofluorescence testing are more frequently
used.16,26 More importantly, the indirect micro-
immunofluorescence (MIF) test is specific for the pathogen
and is still considered as the standard method for
C. pneumoniae detection in sera specimens.27e30
Little is known about either the prevalence of asymp-
tomatic C. pneumoniae infection or the association be-
tween this agent and respiratory and chronic infections in
Jordan. A single study investigated the seropositivity for
C. pneumoniae in male blood donors aged 18e50 years in
Jordan.31 The present study expanded the population-
based survey and aimed, using the MIF serologic test, at
evaluating the seroprevalence of asymptomatic C. pneu-
moniae infection among apparently healthy Jordanian
subjects from both sexes and of various ages.
Materials and methods
Study population and serum collection
A total of 588 subjects attending the outpatient clinics at
the Hospital of the University of Jordan, Amman, Jordan,
were enrolled in this study. They visited the clinics between
December 2008 and May 2009 for various reasons. In-
dividuals were excluded from the study if they had symp-
toms of respiratory disease or received antibiotics within
the last 3 months preceding enrollment. Study subjects
were aged 2e86 years (mean age 36 years) and consisted of
199 males (mean age 35.8 years) and 389 females (mean
age 36.2 years). According to their ages, they were divided
into eight age groups: 2e9 years (n Z 38); 10e19 years
(n Z 61); 20e29 years (n Z 142); 30e39 years (n Z 99);40e49 years (n Z 94); 50e59 years (n Z 84); 60e69 years
(n Z 54); and 70 years (n Z 16). Informed consent was
obtained from all study subjects. This study was approved
by the Scientific Research Committee at the Department of
Biological Sciences and the Hospital of the University of
Jordan.
Aliquots of blood samples drawn for necessary labora-
tory tests were obtained for this study. A single serum
specimen from each individual was prepared and stored
at e20C until tested.
Antigen preparation
The C. pneumoniae strain VR1310, generously provided by
Thomas F. Meyer (Max Planck Institute for Infection Biology,
Berlin, Germany) was used for antigen preparation in the
serologic testing method MIF. Antigens were whole
elementary bodies prepared as described previously,30 with
minor modifications. Briefly, C. pneumoniae were grown in
cell culture, purified by centrifugation, and treated with
0.05% formalin. Before dotting onto wells of immunofluo-
rescence slides, antigens were mixed in 0.5% yolk sac. The
dotted slides were dried and fixed with acetone for 15
minutes at room temperature and then stored at e70C
until used.
Serologic assay
The MIF test is based on the indirect detection of human IgG
antibodies against C. pneumoniae using labeled anti-human
IgG antibodies.30 IgG antibody in sera was first screened at
1:16, a dilution considered a marker for C. pneumoniae
positivity in this study. Positive and negative controls were
also applied in each run at 1:16. Slides were incubated in a
humid chamber at 37C for 1 hour. After washing with PBS
to remove unbound serum antibodies, each antigen spot
was overlaid with fluorescein-labeled goat anti-human IgG
antibody (Bio-Rad, Hercules, CA, USA) and incubated as
before. Slides were then washed, dried, mounted, and
examined using an epifluorescence microscope (Nikon,
Tokyo, Japan) at 400 magnification. If sera were reactive
in MIF at 1:16, they were further tested at serial twofold
dilutions (from 1:16 to 1:512) for IgG antibody titer deter-
mination. A chlamydial IgG antibody titer of 1:16 to 1:256
was considered indicative of past or previous infection and
a titer of 1:512 was defined as a marker for acute or recent
infection.1,11,13,16,20,26,32
Statistical analysis
The statistical significance of the data obtained for sex and
age groups was determined using the Chi-square test. A p
value <0.05 was considered statistically significant.
Results
The prevalence of C. pneumoniae antibodies in Jordan was
evaluated using sera collected from a total of 588 asymp-
tomatic Jordanian nationals (199 males and 389 females).
The mean ages of males and females were 35.8 years and
Table 1 Prevalence of anti-C. pneumoniae IgG antibodies in a healthy Jordanian population by age and sex



















2e9* 28 8 28.6 10 1 10.0 38 9 23.7
10e19 27 10 37.0 34 9 26.5 61 19 31.1
20e29 33 19 57.6 109 52 47.7 142 71 50.0
30e39* 21 15 71.4 78 51 65.4 99 66 66.7
40e49* 25 14 56.0 69 49 71.0 94 63 67.0
50e59 32 20 62.5 52 30 57.7 84 50 59.5
60e69* 23 18 78.3 31 16 51.6 54 34 63.0
70* 10 7 70.0 6 4 66.7 16 11 68.8
Total 199 111 55.8 389 212 54.5 588 323 54.9
a IgG  1:16.
*Statistically significant difference between males and females (p < 0.05).
Figure 1. Distribution of endpoint titers of C. pneumoniae
IgG antibody in the sera of 323 apparently healthy Jordanian
subjects that showed seropositivity by MIF.
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grouped into eight age groups. Table 1 summarizes the
presence of C. pneumoniae IgG antibody in study subjects
according to age and sex. The differences in IgG seroposi-
tivity between males and females were statistically signif-
icant in the age groups 2e9 years, 30e39 years, 40e49
years, 60e69 years, and 70 years. After combining the
sexes, the seroprevalence within the age groups was as
follows: 23.7% in 2e9 years, 31.1% in 10e19 years, 50% in
20e29 years, 66.7% in 30e39 years, 67% in 40e49 years,
59.5% in 50e59 years, 63% in 60e69 years, and 68.8% in 70
years (Table 1).
The IgG detection rate in both sexes under the age of 10
years was the lowest for both males (28.6%) and females
(10%) and increased notably in persons aged 10 years to 39
years (Table 1). When both sexes were combined, mean
seropositivity for persons aged 2e9 years was 23.7% and
steadily increased in the age groups 10e19 years (31.1%)
and 20e29 years (50%) to reach a plateau of 66.7% in the
age group 30e39 years, which remained almost stable to
age 70 years (Table 1).
Overall, the seropositivity in all healthy individuals
tested was 54.9% (323/588). The antibody detection rate
was slightly higher in males (55.8%) than females (54.5%;
p < 0.05). Data obtained in this study on individuals aged
2e18 years old are extrapolated in order to compare the
prevalence of infection in children and teenagers with that
in adult people older than 18 years. The overall prevalence
of C. pneumoniae IgG in children and teenagers of both
sexes (under 18 years old) was 26.4% (19/72), compared to
58.9% (304/516) in adults. In children and teenagers,
C. pneumoniae antibodies were present in 12 out of 43
males (27.9%) and in seven out of 29 females (24.1%). IgG
prevalence in males aging 18 years was 63.5% (99/156),
appreciably higher than in females older than 18 years, who
showed a 56.9% (205/360) prevalence.
Distribution of IgG titers for C. pneumoniae in the
seropositive population (323 individuals) showed a rela-
tively low (23/323, 7.1%) percentage of individuals with an
endpoint titer, i.e., the highest positive dilution, of 1:16.
Individuals with anti-C. pneumoniae IgG detectable at
endpoint levels higher than 1:16 gradually increased andreached 47 (14.6%), 55 (17%), 65 (20.1%), and 84 persons
(26%) at titers 1:32, 1:64, 1:128, and 1:512, respectively.
However, at 1:256, a sharp decrease in IgG titers occurred,
with only 49 (15.2%) subjects testing positive (Fig. 1).
An IgG titer of 1:512 is considered serologic evidence
of a recent infection with C. pneumoniae in this study.
About 14.3% of individuals tested (84/588) had recent
infections: 16.1% of males (32/199) and 13.4% of females
(52/389). The prevalence of recent infection in adults (18
years old) was 14.9% (77/516), which was higher than rates
detected in children and teenagers (9.7%; 7/72). Remark-
ably, recent infections were found in over a quarter (26%)
of the total number of individuals tested positive for
the IgG antibody (84/323 persons). Males with recent
infection represented 28.8% (32/111) of the total number of
seropositive males, whereas females represented 24.5%
(52/212) of the total number of infected females
(p > 0.05). When both sexes were combined, the preva-
lence of recent C. pneumoniae infection was highest in the
age group 10e19 years and in ages over 60 years (Table 2).
Table 2 Prevalence of high anti-C. pneumoniae IgG antibody, indicating possibly a recent infection (seropositivity at titer
1:512), in a seropositive Jordanian population
Age group (y) Males Females Both sexes
Number a % Positivity
at 1:512
Number a % Positivity
at 1:512
Number a % Positivity
at 1:512
2e9 1/8 12.5 1/1 100 2/9 22.2
10e19 4/10 40.0 4/9 44.4 8/19 42.1
20e29 4/19 21.1 13/52 25.0 17/71 23.9
30e39 3/15 20.0 8/51 15.7 11/66 12.1
40e49 3/14 21.4 8/49 16.3 11/63 17.5
50e59 4/20 20.0 10/30 33.3 14/50 28.0
60e69 10/18 55.6 7/16 43.8 17/34 50.0
70 3/7 42.9 1/4 25.0 4/11 36.4
Total 32/111 28.8 52/212 24.5 84/323 26.0
a Number of persons showing seropositivity at 1:512/total number of seropositive cases.
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The prevalence of C. pneumoniae IgG antibody was
assessed in a total of 588 apparently healthy Jordanian
males and females, aged 2e86 years, using the MIF tech-
nique. Serology is the method of choice in routine clinical
laboratories for diagnosis of C. pneumoniae infection.11 In
particular, MIF has been widely used to detect exposure
rates to C. pneumoniae28,29 and is considered the only
currently acceptable serologic test.27
Most epidemiological studies published so far recom-
mended the use of 1:16 as serologic evidence of C. pneu-
moniae infection.1,11,15,20e22,24,26,27,32e34 A limited number
have used 1:8,35 1:32,13,16,18,19,36,37 or 1:64.38 Nevertheless,
studies performed worldwide have estimated exposure
rates ranging from 40% to 86% in most adult populations,
suggesting that C. pneumoniae infection is endemic in many
countries and widely distributed. Here, the prevalence of
C. pneumoniae infection was evaluated using the titer of
1:16. A high prevalence of C. pneumoniae IgG antibody
(54.9%) was demonstrated in the Jordanian population. This
prevalence is in agreement with exposure rates assessed in
healthy populations worldwide; for instance, overall sero-
positivity in Turkey, Slovenia, Taiwan, Japan, and Korea is
estimated at 41.5%, 41.6%, 55.8%, 52%, and 52%, respec-
tively.13,18,21,22,33 Prevalence of C. pneumoniae in Jordanian
adults (58.9%) is moderate and comparable to estimates in
other asymptomatic adult populations, which range from
40% to 86%. Exposure rates in adults are 48.4e60.9% in
Japan,18,24 56e77.7% in Finland,19,35,37 49.4% in Slovenia,21
64.9% in Germany,15 64.5% in Turkey,33 75.2% in Hungary,34
72.3% in Taiwan,22 40e86% in USA,8,16,20 53% in Iceland,14
61.6% in Korea,13 and 64% in Sudan.23 The prevalence rate
of C. pneumoniae in Jordanian children and teenagers (<18
years old), however, was markedly lower (26.4%), a rate also
comparable to those previously reported for healthy chil-
dren and teenagers in other countries such as Slovenia (with
a detection rate of 26% in school age children) as well as
Finland and Hungary (rural areas) with rates of 27% and
22.7%, respectively.19,21,34 However, markedly lower or
higher rates of prevalence in children in Turkey and Korea
have also been reported.22,33 Thus, asymptomatic C.pneumoniae infection is common in Jordan, with seropre-
valence rates comparable to other countries around the
world.
The prevalence of the C. pneumoniae antibody was
23.7% in children between 2 years old and 9 years old.
Detection of the antibody increased rapidly in older chil-
dren and teenagers (10e19 years old), indicating that the
primary exposure to C. pneumoniae begins in children and
young people. The seropositivity continued to increase in
adults, and in the age group 30e39 years, it reached a
plateau of 66.7%, which remained almost stable in older
individuals. Collectively, the present study demonstrates
that infection is acquired during the first four decades of
life, and that the stable high rates of C. pneumoniae
infection in elderly subjects might be the result of persis-
tent infection or frequent reinfection.9,39,40 Importantly,
an obvious relationship between sex and the prevalence of
the C. pneumoniae antibody was found. Prevalence rates
were higher in males than in females in all age groups,
except the 40e49 years group. This seemingly anomalous
result might be due to the relatively low numbers of males
investigated within this age bracket. The higher prevalence
rates among males observed here is fully consistent with
previous reports.13,15,17,21,22,24,32,33,36e38 Previous work has
attributed the higher prevalence in males to a greater
proportion of men working outside the home than women.39
However, this assumption cannot explain differences
observed here and by Kese and coworkers,21 between sexes
of non-working subjects under the age of 18 years. Hence,
further work is needed to clarify the underlying factor(s)
responsible for sex-associated differences in the preva-
lence of C. pneumoniae.
In a previous study, the prevalence of C. pneumoniae
antibodies in Jordanian blood-donating adult males aged
20e50 years was assessed using MIF.31 The IgG seropositivity
estimated in adult males was 63.3%.31 This detection rate is
almost equal to the IgG prevalence (63.5%) detected here in
males aging 18 years. When extrapolated from the data
presented in Table 1, the overall prevalence of C. pneu-
moniae IgG in adult males between 20 years and 50 years
was 60.8%, a percentage that is still approximately com-
parable to that assessed previously for males within the
same age range.31 In addition, both studies indicate that
416 H.M. Al-Younesthe primary infection is acquired during the first four de-
cades of life.
Criteria for the definition of recent (acute or current)
infection of C. pneumoniae using IgG class in MIF appear to
be controversial. IgG titers 1:25622 and more frequently
1:5121,11,13,15,16,20,24,26,37 were defined as evidence
for recent infection using one serum sample. Others
considered IgG titers of 512 as indicative of a “possible”
recent infection,27 when single serum is used. Another
criterion for recent infection is a fourfold titer rise in IgG
levels between two consecutive sera.27,35 Here, there were
difficulties in obtaining paired serum samples from subjects
examined. However, considering a titer of 1:512 was diag-
nostic of a recent infection allowed us to compare our re-
sults with the majority of previous reports. Surprisingly,
acute infection was detected in 14.3% of apparently
healthy Jordanian subjects aged between 2 years and 86
years. This rate is among the highest; for instance, preva-
lence rates of 3.7% and 4.5% have been reported in Korean
and Taiwanese populations, respectively.13,22 Elevated
antibody titers observed in the present study indicate that
some individuals had experienced recent subclinical
(asymptomatic) infections. Nearly 15% of Jordanian adults
showed serologic evidence of a recent infection. High rates
were also demonstrated in healthy adults (about 18%) in
Brooklyn, USA.16,26 However, the prevalence of recent
infection in Jordanian adults is considerably higher than
those reported in asymptomatic Taiwanese (6.4%), Japa-
nese (3.9%), and German (3.4%) adults.15,22,24 Variations in
serologic results may reflect differences in geographic
areas, ages of subjects investigated, and the time periods
in which serum samples were collected.
The present work is the first to demonstrate the seroe-
pidemiologic profile of asymptomatic C. pneumoniae
infection in the Jordanian population. The high overall
prevalence of antibodies suggests that C. pneumoniae is
endemic in Jordan. Further surveys are recommended to
correlate the pathogen with different relevant clinical
manifestations such as respiratory system and coronary
heart diseases in Jordan.Conflicts of interest
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